IGF-1 Disappoints in Trials for AD, ALS

November was a dreary month for those who had high hopes for insulin-like growth factor-1 as a treatment for neurodegenerative disorders. Though IGF-1 still has potential, therapies based on the growth factor failed in two clinical trials published last month. Researchers at the Mayo Clinic in Rochester, Minnesota, administered IGF-1 to patients with amyotrophic lateral sclerosis for two years, hoping to replicate the beneficial effect of a prior trial. They found no improvement in strength, daily functioning, or lifespan, as reported in the November 25 issue of Neurology. One week earlier, also writing in Neurology, scientists at Merck’s North Wales, Pennsylvania, campus reported that a drug that enhances IGF-1 secretion had no benefit for people with Alzheimer disease over a one-year trial.

There is still a shred of hope to cling to, however. The Merck scientists, led by Jeffrey Sevigny, did find benefit for patients with a specific genotype, those who did not carry the apolipoprotein E (ApoE) ε4 allele, a major risk factor for late-onset AD. And although the ALS trial, led by Mayo Clinic scientist Eric Sorenson, showed no effect for subcutaneous IGF-1 injections, it’s still possible that IGF-1 could be beneficial if delivered via an alternate route.

No Help for Struggling Motor Neurons

However, Sorenson said the most likely explanation for his results is that IGF-1 is not an effective ALS treatment. The work dashes the hopes of doctors, patients, and the drug company, Cephalon, based in Frazer, Pennsylvania, that wanted to market the therapy. The theory was promising: in animals and in vitro systems, IGF-1 promotes growth of motor neurons, the cells that degrade and die in ALS (Nagano et al., 2005; Dobrowolny et al., 2005). It also protects motor neurons from the toxic effects of the neurotransmitter glutamate, which has been linked to ALS pathology (see ARF related news story). IGF-1’s track record in ALS, however, was spotty. Two previous clinical trials in the 1990s had opposite results: one found no effect for IGF-1 (Borasio et al., 1998); the other tracked a slowing of symptom progression in patients receiving the growth factor (Lai et al., 1997). A more recent study found no benefit for overexpressed IGF-1 in a mouse ALS model (Messi et al., 2007).

Those two conflicting human trials prevented approval from the Food and Drug Administration, but IGF-1 has been used off-label in other countries, Sorenson said. The new study was the result of continuing interest from patients as well as Cephalon. Hopefully, it provides an answer to the dilemma that this drug was in, he said. Our data were very clean, it was consistent, it did not leave any doubts in my mind. Unlike the earlier work, this study followed subjects (330) for two years instead of nine months, administering the highest IGF-1 dose (0.05 mg/kg body weight twice daily) that was tolerated in the previous studies. Three straightforward outcome measures—composite strength, survival, and the ALS functional rating scale, which considers performance measures for day-to-day tasks such as swallowing, breathing, and getting dressed—showed no difference between IGF-1 and placebo. The previous positive results, Sorenson said, were likely due to chance.

Given the subcutaneous delivery method, the study results are not so surprising, said Antonio Musar of the Sapienza University of Rome, Italy, who did not take part in either study. Previous research that showed a positive effect for IGF-1 in a mouse model of ALS used viral delivery of the IGF-1 gene (Kaspar et al., 2003 and see ARF related news story). It’s very possible that the drug is not getting where it needs to get, Sorenson agreed. Other researchers are now exploring more direct delivery of the growth factor to the cells of the central nervous system, Sorenson said, via infusion, gene therapy, or stem cell transplant.

And Apparently No Plaque Relief

The Merck study used the compound MK-677, which boosts circulating IGF-1 levels when given orally (Chapman et al., 1996). The theory behind the trial was that IGF-1 mediates clearance of Aβ in the brain, and thus should destroy the plaques that hypothetically cause Alzheimer’s symptoms (Carro et al., 2002). People with AD have decreased sensitivity to insulin and IGF-1 in the brain, and lower circulating levels of IGF-1, suggesting the hormones may not be doing their jobs effectively. However, a recent Pfizer study found increased IGF-1 did not affect Aβ clearance in several animal models (Lanz et al., 2008), hinting the IGF-1 hypothesis was shaky to begin with, said Konrad Talbot of the University of Pennsylvania School of Medicine in Philadelphia, who was not involved with either study.

Patients with mild to moderate AD receiving the drug showed a 60 percent or more increase in serum IGF-1 levels within six weeks. Yet the yearlong study found no benefit based on standard scores of overall symptoms, cognitive ability, dementia, and daily living function. You get the impression that this is not the way to go to induce Aβ clearance from the brain, Talbot said. However, the scientists did not directly monitor Aβ levels or look for clearing of plaques in the brain, so it is not certain if the drug affected Aβ pathology or not. It is also possible that Aβ, accumulated over several years, had simply caused too much damage before the treatment.

The subject number—416 patients completed the study—could have been bigger, Talbot said. Once the scientists sorted the subjects into subgroups of baseline symptoms, race, gender, ApoE genotype and other treatments used, and by drug or placebo, the number of individuals in each group was relatively small. Talbot would have liked to see twice as many patients, but said, My gut feeling is it [patient number] didn’t affect the results they obtained.

Talbot noted that the one group that did get some benefit from the drug was people who did not have the ApoE4 allele. That would be worth studying, he said. Insulin response is also sensitive to ApoE genotype (Craft et al., 2003), suggesting that people with or without the ApoE4 allele may respond differently to the insulin family of hormones.

With improved delivery and targeting, it’s possible that IGF-1 could still be a beneficial treatment for neurodegenerative disorders. At least, both studies confirmed the therapies are safe. It’s interesting enough that I would not give up on it yet, Sorenson said.

References:
Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008 November 71:1770-1775. Abstract

Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML. Growth hormone secretagogue MK-677: no clinical effect on AD progression in randomized trial. Neurology 2008 November 71:1702-1708. Abstract


To view commentaries, primary articles and linked stories, go to the original posting on Alzforum.org here.

Copyright © 1996–2015 Biomedical Research Forum, LLC. All Rights Reserved.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail